Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index; 74 of the 161 sources its claims cite were checked for support.

Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis

Open access
Sun, Frances Sze Kei, Wong, Jeffrey Sum Lung, Mak, Lung-Yi, Wong, Carmen Chak-Lui, Chew, Valerie, Li, Bryan Cho Wing, Leung, Roland, Cheung, Tan To, Yau, Thomas · 2025 · Liver Cancer

Abstract

Background: Immune checkpoint inhibitors (ICI) are a keystone in advanced hepatocellular carcinoma (aHCC) therapy. However, preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs. This has tremendous implications for both therapy selection and future drug development. Summary: Viral and MASH-HCCs differ in molecular pathogenesis and immune microenvironment. Preclinical evidence has shown impaired immune surveillance and ICI-induced auto-aggressive T cells in pure MASH-HCC. Phase 3 clinical trials and meta-analyses have conflicting outcomes. For single-ICI regimens with anti-programmed-death 1/L1 (anti-PD1/L1), there was no apparent difference in the overall survival for patients with non-viral HCCs in the CheckMate-459, IMbrave150, COSMIC-312, and KEYNOTE-240 trials for ICI over tyrosine-kinase inhibitors or placebo, while patients with viral hepatitis seemed to have benefited more. Meanwhile, comparable outcomes were seen for patients with viral and non-viral HCCs in the HIMALAYA, RATIONALE-301, LEAP-002, and CARES-310 trials. There was no consistent difference in outcomes between patients with HBV or HCV-HCCs. For dual-ICI regimens with anti-PD1/L1 and anti-cytotoxic T-lymphocyte associated protein-4 (anti-CTLA-4), the HIMALAYA and CheckMate-9DW trials showed similar efficacy for ICI combinations across all etiologies. Important caveats in interpreting current evidence exist. All trial data are from unplanned subgroup analyses only, limiting the level of clinical evidence available. "Non-viral HCCs" are also a heterogenous entity, the composition of which varies from trial to trial. Fundamentally, defining HCC etiologies, especially in mutually exclusive terms, is challenging: Occult hepatitis B infections are inconsistently tested and reported; hence, viral HCCs may be underreported. HCCs are often multifactorial, with steatosis frequently co-existing and interacting with viral hepatitis, creating difficulty in translating findings from pure MASH-HCC mouse models. Key Messages: Current evidence is insufficient to support individualizing aHCC treatment based on etiology. Preclinical evidence for a lesser benefit with ICIs in MASH-HCCs exists, while data from clinical trials are mixed but limited. Major gaps in knowledge remain, and further studies are required to clarify this important subject.

Overview

CoChat Summary

## TL;DR

This narrative review concludes that current evidence is insufficient to support tailoring unresectable/advanced HCC treatment by etiology, even though preclinical studies suggest ICIs may be less effective or potentially harmful in pure MASH-HCC. Across phase 3 trials and meta-analyses, results are mixed, with more consistent benefit for viral HCCs in some single-ICI studies and preserved efficacy of dual-ICI regimens across etiologies.

## Key findings

  • Preclinical studies in NASH/MASH models found that anti-PD1 therapy could worsen NASH and increase HCC incidence, and that mice with pure MASH-HCC may not benefit from ICIs.
  • In CheckMate-459, OS HRs for nivolumab vs sorafenib were 0.77 for HBV-HCC, 0.71 for HCV-HCC, and 0.95 for non-viral HCC; ORRs were 19%, 17%, and 12%, respectively, versus 7–8% with sorafenib.
  • In KEYNOTE-240, pembrolizumab vs placebo showed a numerically greater OS benefit in HBV-HCC (HR 0.57) than in non-viral HCC (HR 0.88); the authors note only 15.5% of patients had HCV-HCC.
  • Meta-analyses were inconsistent: one pooled analysis of 3 ICI trials (n = 1,656) found better OS in viral than non-viral HCCs (HR 0.64 vs 0.92, p for heterogeneity = 0.0259), while a later meta-analysis found OS benefit in both viral and non-viral HCCs (HR 0.79 overall; HBV 0.70, HCV 0.78, non-viral 0.87).

## Methods

  • Narrative review of preclinical, translational, and clinical literature on ICI use in HCC across etiologies, focusing on viral hepatitis and MASH-related HCC.
  • Literature searches were conducted in electronic databases such as PubMed, restricted to English-language publications, with additional citation chasing from retrieved papers.
  • The paper synthesizes phase 3 trial subgroup analyses and meta-analyses; no primary patient-level dataset or original statistical analysis was performed by the authors.

## Limitations

  • The paper states that most clinical evidence comes from unplanned subgroup analyses that are not powered for formal comparison, and meta-analyses are based on trial-level rather than individual patient data.
  • The paper states that etiology definitions are inconsistent across trials, including variable testing for occult HBV and lack of biopsy-based confirmation of MASH; “non-viral” groups are heterogeneous.
  • Evident from the text: the review’s clinical conclusions are constrained by incomplete reporting of baseline characteristics, toxicities, ORR/DCR, survival curves, and post-progression therapy by etiology, so findings remain hypothesis-generating rather than definitive.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1159/000548536

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Contribution of etiology to incidence of primary liver cancer by region in 2021.
Fig. 1. Contribution of etiology to incidence of primary liver cancer by region in 2021.CC BY-NC · PubMed Central
Fig. 2. Different pathogenesis and immunopathology of HCC etiologies.
Fig. 2. Different pathogenesis and immunopathology of HCC etiologies.CC BY-NC · PubMed Central
Fig. 3. Summary and forest plots of OS with ICI-based regime in phase III trials.
Fig. 3. Summary and forest plots of OS with ICI-based regime in phase III trials.CC BY-NC · PubMed Central
Fig. 4. Summary and forest plots of progression-free survival with ICI-based regime in phase III trials.
Fig. 4. Summary and forest plots of progression-free survival with ICI-based regime in phase III trials.CC BY-NC · PubMed Central
Fig. 5. Interaction between viral hepatitis and steatosis.
Fig. 5. Interaction between viral hepatitis and steatosis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

28 Valid · 31 Not valid · 65 Not checked · 60 Own results and interpretations

137 more claims · 40 with their cited sources checked

Create a free account to see all 184 claims and to verify the 29 references still open.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 96 references

Cited by

See all 3

Metadata

Authors
Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T.
Affiliations
  • Queen Mary Hospital (CN)
  • University of Hong Kong (HK)
  • SingHealth (SG)
Corresponding author
Yau, Thomas
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2025-09-19
Volume
15
Issue
3
Pages
480-496
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
OpenAlex
W7082294778
Cited by
3
References
96
Citations by year
2026: 3
FWCI
0.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Liver Cancer (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords
advanced hepatocellular carcinoma, immune checkpoint inhibitors, nonalcoholic steatohepatitis, viral hepatitis, hepatitis B, hepatitis C, cancer etiology, PD-1/PD-L1 blockade, CTLA-4 blockade, immune microenvironment, immune surveillance, subgroup analysis, tyrosine kinase inhibitors, steatosis, treatment selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis. https://app.cochat.ai/papers/10.1159/000548536
The paper
Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T. (2025). Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis. Liver Cancer. https://doi.org/10.1159/000548536

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.